PHG Stock Analysis: Buy, Sell, or Hold?
PHG - KONINKLIJKE PHILIPS N.V.
$27.74
0.54 (1.99%)
▲
5d:
+1.65%
30d:
+9.08%
90d:
+1.65%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 28, 2026
23d
Get Alerted When PHG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PHG shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PHG shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$43.13
Based on 8.4% avg growth
INTRINSIC VALUE TODAY
$26.78
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHG is currently trading at $27.74, which is considered extended relative to its 30-day fair value range of $25.95 to $27.00. The stock's valuation (Forward PE: 13.7) is in line with its historical norms (14.3). Remarkably, the market is currently pricing in an annual earnings decline of 1.2% over the next few years. This pessimistic expectation contrasts with the company's recent 97.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PHG is in a strong downtrend. The price is approaching resistance at $27.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PHG has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $33.26 (+19.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PHG is in a strong downtrend. The price is approaching resistance at $27.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PHG has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $33.26 (+19.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$25.95 -
$27.00
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
59.5%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($33.26)
Trading Range Analysis
30-Day Trading Range
$25.95 -
$27.00
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$26.25
Resistance Level
$27.85
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.74
Wall Street Target
$33.26
(+19.9%)
Revenue Growth (YoY)
-4.7%
Earnings Growth (YoY)
97.2%
Profit Margin
5.5%
Valuation Discount vs History
-1.2% cheaper
PE vs Historical
13.7 vs 14.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.2%
(market-implied from PE analysis)
1-Year Target
$27.41
(-1%)
2-Year Target
$27.08
(-2%)
3-Year Target
$26.75
(-4%)
3-Yr Target (if PE normalizes)
(PE: 14→14)
$27.85
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 12.8%)
$63.18
(+128%)
Base:
(SPY PE: 13.7, Growth: 12.8%)
$39.85
(+44%)
Bear:
(PE: 11.7, Growth: 12.8%)
$33.87
(+22%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 23.86 | Current EPS (TTM): $1.14
Bull Case
$53.00
(+91%)
Analyst growth 77.1%, PE expands to 26.3
Base Case
$48.18
(+74%)
Market implied 77.1%, PE stable at 23.9
Bear Case
$18.50
(-33%)
Severe decline -20.0%, PE contracts to 20.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.7 to 14.3
Stabilization Target:
$28.87
(+4.1%)
PE Expansion Potential:
+4.1%
Share & Embed Analysis
Last updated: July 04, 2026 8:27 AM ET
Data refreshes hourly during market hours. Next update: 9:27 AM
Data refreshes hourly during market hours. Next update: 9:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 63 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 65 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 65 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 65 BUY |
